Korean J Med.
2000 Feb;58(2):180-188.
Anti-hyperglycemic, anti-hypertriglyceridemic and stimulatory effect on
glucose transporter 4 mRNA appearance of hydrolysable tannins(Rosanin) of the rosa
rugosa root in the streptozotocin-injected diabetic rats
- Affiliations
-
- 1Department of Forest Products & Technology, College of Agriculture, Chonbuk National University, Chonju, 561-756, Seoul, Korea.
Abstract
-
BACKGROUND: The root of the plant Rosa rugosa has been reported to have an
anti- hyperglycemic and anti-hyperlipidemic effect in experimental animals.
But its definite anti-hyperglycemic and anti-hyperlipidemic substance has
not yet been identified. In this study, we found the hydrolysable tannins
of the hot water extract of the Rosa rugosa root had those effects, and
named it as Rosanin. And its mode of actions were evaluated.
METHODS
Three groups of streptozotocin-injected rats and two groups of
buffer-injected control rats were given 10 mg/Kg/ml of Rosanin, or
glibenclamide, or water by nasogastric tubes for three weeks. Blood sugar,
insulin, triglyceride and GLUT4 mRNA levels were checked in the fasting state.
Liver, kidney and pancreatic specimens were observed by light microscopy.
RESULTS
All the water-treated, glibenclamide-treated and Rosanin-treated
diabetic rats had significantly higher blood sugar levels compared to that
of normal control rats (p< 0.001, p< 0.001 and p< 0.05,
respectively); but Rosanin-treated diabetic rats had significantly lower blood
sugar level compared to those of glibenclamide-treated and water-treated
diabetic rats (p< 0.05 and p< 0.001, respectively). In the Northern
blot analysis from the experimental rats' hind limb skeletal muscle RNA,
all the diabetic rats showed variously decreased levels of GLUT4 mRNA compared
to those of normal control rats. The water-treated diabetic group showed a 66%
decline (p< 0.001); the glibenclamide-treated diabetic group led with a 2%
decline; and the Rosanin-treated diabetic group revealed a 23% decline
(p< 0.05). All three groups of diabetic rats had significantly lower
insulin levels compared to that of normal control rats (p< 0.01),
but glibenclamide-treated diabetic rats and Rosanin-treated diabetic rats
had significantly higher insulin level compared to that of water-treated
diabetic rats (p< 0.05, each).
Furthermore, Rosanin treatment significantly decreased plasma blood triglyceride
levels of streptozotocin-injected diabetic rats compared to water-treated
and glibenclamide-treated, streptozotocin-injected diabetic rats
(p< 0.05 and p< 0.01, respectively). The light microscopic observation of
pancreatic specimens of the Rosanin-treated diabetic group showed more intact
islet cells than the water-treated diabetic groups. Liver specimens of the
Rosanin-treated diabetic group showed a normal appearance, but those of the
water-treated diabetic groups showed severe spotty hepatic necrosis
and many regenerating hepatic cells.
CONCLUSION
Rosanin has an anti-hyperglycemic effect. This effect is due, in part,
through the enhancement of the GLUT4 mRNA expression, the stimulation of insulin
secretion in hyperglycemia, and through the preservation of pancreatic beta
cells from the destructory damages of the streptozotocin. Further, it has
anti-hypertriglyceridemic and hepatotoxicity-relieving effects in streptozotocin-injected
diabetic animals. Abbreviations : Rosanin, the high molecular weight hydrolysable
tannins of the hot water extract of the Rosa rugosa root; has an
average molecular weight of about 830,000; it mainly consists of D-glucose
units linked by the 1-->4 gulcoside bonds and phenolic acids, such as
ellagic and gallic acid1).